Li J, et al. - This secondary analysis of phase II clinical trial data was undertaken to determine if time to progression (TTP) was associated with post-progression survival (PPS) among previously treated patients with metastatic v-Raf murine sarcoma viral oncogene homolog B V600E non-small cell lung cancer (NSCLC) receiving dabrafenib as monotherapy or in combination with trametinib. The data presented in this work showed a longer TTP duration after treatment with dabrafenib monotherapy or combination therapy was related to significantly longer PPS duration.